Back to Search
HOWARD SCHER, MD
MD
Medical Oncology Physician
NPI: 1689645533Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
131278(NY)
Research & Publications (20)
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.
PMID 19213602·Lancet Oncol·2009
8-other
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
PMID 18309951·J Clin Oncol·2008
6-review
The association between measures of progression and survival in castrate-metastatic prostate cancer.
PMID 17332293·Clin Cancer Res·2007
8-other
Prostate cancer clinical trial end points: "RECIST"ing a step backwards.
PMID 16033840·Clin Cancer Res·2005
6-review
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.
PMID 16278481·J Clin Oncol·2005
6-review
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer.
PMID 15369448·Endocr Relat Cancer·2004
6-review
Current management of hormone-refractory prostate cancer.
PMID 16163259·Clin Adv Hematol Oncol·2004
8-other
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.
PMID 14752077·J Clin Oncol·2004
6-review
Prostate carcinoma: defining therapeutic objectives and improving overall outcomes.
PMID 12548573·Cancer·2003
6-review
Clinical states in prostate cancer: toward a dynamic model of disease progression.
PMID 10699601·Urology·2000
8-other
Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease.
PMID 19624594·BJU Int·2010
8-other
NF-kappaB regulates androgen receptor expression and prostate cancer growth.
PMID 19628766·Am J Pathol·2009
7-preclinical
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.
PMID 19364960·J Clin Oncol·2009
3-trial
Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer.
PMID 19276271·Clin Cancer Res·2009
8-other
A novel androgen receptor amino terminal region reveals two classes of amino/carboxyl interaction-deficient variants with divergent capacity to activate responsive sites in chromatin.
PMID 19282387·Endocrinology·2009
7-preclinical
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
PMID 19359544·Science·2009
3-trial
Bone marrow aspiration for disseminated tumor cell detection: a must-have test or is the jury still out?
PMID 19237625·J Clin Oncol·2009
8-other
Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.
PMID 19638458·Clin Cancer Res·2009
6-review
Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer.
PMID 19375217·Eur Urol·2009
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1275 YORK AVE
NEW YORK, NY 10021 - Phone
- (212) 639-2000
Quick Facts
- NPI
- 1689645533
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile